TACTUM: Trends in access to cellular therapies in multiple myeloma, perspectives of treating versus referring physicians Journal Article


Authors: Atallah, R.; Ahmed, N.; Ayoobkhan, F.; Saif, M. S. I.; Logan, E.; Shrestha, A.; Anwer, F.; Mahmoudjafari, Z.; Mushtaq, M. U.; Hashmi, H.; Ganguly, S.; McGuirk, J.; Shebli, A.; Abdallah, A.; Banerjee, R.; Alkharabsheh, O.
Article Title: TACTUM: Trends in access to cellular therapies in multiple myeloma, perspectives of treating versus referring physicians
Abstract: Chimeric antigen receptor T cell therapy (CAR-T) and bispecific T cell engagers (TCE) for multiple myeloma (MM) are readily available at many large US medical centers. However, many potentially eligible patients may not be referred to the specialized centers administering these therapies. Perspectives regarding potential barriers for MM cellular therapy from referring-center oncologists (ROs) versus treating-center oncologists (TOs) have not been reported previously. We conducted TACTUM-23, a survey of US oncologists who treat MM, to identify perceived barriers to these cellular therapies. This 24- question survey, which focused on demographics and perceived barriers to CAR-T and TCE, was conducted between June and August 2023. Of 247 oncologists, 37 (15%) completed the survey including 26 (70%) TOs who prescribed both CAR-T and TCEs, 4 (11%) TOs who only prescribed TCEs, and 7 (19%) ROs who referred patients. The top RO-stated barrier to CAR-T was financial toxicity, while the top TO-stated barrier to CAR-T was leukapheresis/ manufacturing slot availability. The top RO-stated barrier to TCE was financial toxicity, while the top TO-stated barrier to TCE was the hospitalization requirement. In conclusion, financial concerns are perceived by ROs to be the top barrier to both CAR-T and TCEs in myeloma. In contrast, TOs perceive logistical concerns to be the top barrier. Interventions to lower financial toxicity during these therapies, and outreach to raise awareness of such interventions among ROs, are needed alongside strategies to streamline manufacturing (for CAR-T) and monitoring. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.
Keywords: barriers; multiple; chimeric antigen receptor t cell; multiple myeloma treatment access; therapies (cart); bispecific t cell engagers (tce); myeloma treating oncologists, multiple
Journal Title: Transplantation and Cellular Therapy
Volume: 30
Issue: 9
ISSN: 2666-6375
Publisher: Elsevier Inc.  
Date Published: 2024-09-01
Start Page: 925e1
End Page: 925e6
Language: English
ACCESSION: WOS:001305024200001
DOI: 10.1016/j.jtct.2024.05.011
PROVIDER: wos
PUBMED: 38763416
Notes: Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Hamza Hashmi
    62 Hashmi